Clinical Trial Update: A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating SG301 in combination with pomalidomide and dexamethasone vs placebo with pomalidomide and dexamethasone in relapsed or refractory multi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Pomalidomide (Pomalidomide)
• SG301

Snippet

Sponsor: Hangzhou Sumgen Biotech Co., Ltd. | Conditions: Relapsed/Refractory Multiple Myeloma | Phase 3 | Status: RECRUITING